Cargando…
Targeting oncogenic KRasG13C with nucleotide-based covalent inhibitors
Mutations within Ras proteins represent major drivers in human cancer. In this study, we report the structure-based design, synthesis, as well as biochemical and cellular evaluation of nucleotide-based covalent inhibitors for KRasG13C, an important oncogenic mutant of Ras that has not been successfu...
Autores principales: | Goebel, Lisa, Kirschner, Tonia, Koska, Sandra, Rai, Amrita, Janning, Petra, Maffini, Stefano, Vatheuer, Helge, Czodrowski, Paul, Goody, Roger S, Müller, Matthias P, Rauh, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042540/ https://www.ncbi.nlm.nih.gov/pubmed/36972177 http://dx.doi.org/10.7554/eLife.82184 |
Ejemplares similares
-
KRasG12C inhibitors in clinical trials: a short historical perspective
por: Goebel, Lisa, et al.
Publicado: (2020) -
Role and regulation of Yap in KrasG12D-induced lung cancer
por: Mao, Yaopan, et al.
Publicado: (2017) -
Covalent disruptor of YAP-TEAD association suppresses defective Hippo signaling
por: Fan, Mengyang, et al.
Publicado: (2022) -
Mechanisms of nucleotide selection by telomerase
por: Schaich, Matthew A, et al.
Publicado: (2020) -
Nucleotide based covalent inhibitors of KRas can only be efficient in vivo if they bind reversibly with GTP-like affinity
por: Müller, Matthias P., et al.
Publicado: (2017)